The latest quarterly R&D expense is $23.77 Million with a QoQ Growth of -13.92%. Research and Development (R&D) expenses represent the costs incurred by a company in developing new products, services, or processes.
Q2 FY2026 (2026-06-30).
Reported quarterly R&D expense; no daily interpolation. Q2 FY2026 (2026-06-30): $23.77M.
$23.77M
$23.77 Million
Q2 FY2026 · 2026-06-30
-13.92%
vs. $27.61M prior quarter
23
Quarters of data available
| Period | R&D Expense | QoQ Growth | YoY Growth |
|---|---|---|---|
| Q2 FY2026Period end 2026-06-30 | $23.77M | -13.92% | -12.22% |
| Q1 FY2026Period end 2026-03-31 | $27.61M | +30.82% | +24.82% |
| Q4 FY2025Period end 2025-12-31 | $21.11M | +6.30% | -7.81% |
| Q3 FY2025Period end 2025-09-30 | $19.86M | -26.67% | -6.51% |
| Q2 FY2025Period end 2025-06-30 | $27.08M | +22.41% | +17.01% |
| Q1 FY2025Period end 2025-03-31 | $22.12M | -3.38% | -39.58% |
| Q4 FY2024Period end 2024-12-31 | $22.89M | +7.79% | -49.03% |
| Q3 FY2024Period end 2024-09-30 | $21.24M | -8.22% | -29.30% |
| Q2 FY2024Period end 2024-06-30 | $23.14M | -36.79% | -20.33% |
| Q1 FY2024Period end 2024-03-31 | $36.61M | -18.49% | +51.32% |
| Q4 FY2023Period end 2023-12-31 | $44.91M | +49.53% | +96.88% |
| Q3 FY2023Period end 2023-09-30 | $30.04M | +3.42% | +20.56% |
| Q2 FY2023Period end 2023-06-30 | $29.04M | +20.06% | +19.72% |
| Q1 FY2023Period end 2023-03-31 | $24.19M | +6.04% | +12.71% |
| Q4 FY2022Period end 2022-12-31 | $22.81M | -8.43% | +70.32% |
| Q3 FY2022Period end 2022-09-30 | $24.91M | +2.70% | +93.84% |
| Q2 FY2022Period end 2022-06-30 | $24.26M | +13.02% | +121.97% |
| Q1 FY2022Period end 2022-03-31 | $21.46M | +60.25% | +212.70% |
| Q4 FY2021Period end 2021-12-31 | $13.39M | +4.21% | +167.19% |
| Q3 FY2021Period end 2021-09-30 | $12.85M | +17.60% | N/A |
| Q2 FY2021Period end 2021-06-30 | $10.93M | +59.22% | N/A |
| Q1 FY2021Period end 2021-03-31 | $6.86M | +36.92% | N/A |
| Q4 FY2020Period end 2020-12-31 | $5.01M | N/A | N/A |
Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.
